Reshma Kewalramani

Chief Executive Officer and President · Vertex Pharmaceuticals

Biopharmaceuticals

Reshma Kewalramani is chief executive officer and president of Vertex Pharmaceuticals. A physician trained in internal medicine and nephrology, she moved into drug development at Amgen before joining Vertex and becoming its CEO in 2020.

Last reviewed: Oct 31, 2026

Reshma Kewalramani

Chief Executive Officer and President
Vertex Pharmaceuticals

Last Reviewed: October 31, 2026

Executive Summary

Reshma Kewalramani is chief executive officer and president of Vertex Pharmaceuticals. A physician trained in internal medicine and nephrology, she moved into drug development at Amgen before joining Vertex and becoming its CEO in 2020.

Career Highlights

  • Became Vertex president and CEO on April 1, 2020.
  • Joined Vertex in February 2017 and became chief medical officer in April 2018.
  • Previously served as vice president and head of Amgen’s U.S. Medical Organization.

Professional Journey

Kewalramani trained in internal medicine at Massachusetts General Hospital, completing her internship and residency there. She then undertook a nephrology fellowship through the combined Massachusetts General Hospital and Brigham and Women’s Hospital program before moving into the biopharmaceutical industry.

She joined Amgen in 2004 and spent more than twelve years there in clinical development and medical affairs. Her responsibilities expanded across research, development and commercialization, and she ultimately became vice president and head of the U.S. Medical Organization.

Kewalramani joined Vertex in February 2017 as a senior vice president in clinical development and medical affairs. On April 1, 2018, she succeeded Jeffrey Chodakewitz as chief medical officer and executive vice president of Global Medicines Development and Medical Affairs. That position placed her in charge of the clinical and medical organization before her move into company leadership.

She became president and chief executive officer on April 1, 2020. Her leadership has spanned Vertex’s established cystic fibrosis business and its expansion into additional areas of medicine, including gene-edited therapies and pain medicines.

Her professional service has included representing industry on the FDA’s Endocrine and Metabolic Drug Advisory Committee from 2014 to 2019 and serving on the inaugural board of the Kidney Health Initiative. She also serves on the boards of the Biomedical Science Careers Program and Mass General Brigham, and on Boston University’s medical-school dean’s advisory board.

Education

Kewalramani earned a Bachelor of Arts from Boston University and her medical degree, with honors, through its seven-year medical program. She completed internal medicine residency and nephrology fellowship training in Boston. She also completed Harvard Business School’s General Management Program, an executive education program.